Johnny N Mahlangu
Overview
Explore the profile of Johnny N Mahlangu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
875
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mahlangu J, Luis Lamas J, Cristobal Morales J, Malan D, Salek S, Wang M, et al.
Br J Haematol
. 2022 Aug;
200(2):229-239.
PMID: 35999026
A phase 1b/2, three-month study of marstacimab, a human monoclonal antibody targeting tissue factor pathway inhibitor (TFPI), was conducted in participants with haemophilia A or B, with or without inhibitors....
2.
Chowdary P, Holmstrom M, Mahlangu J, Ozelo M, Pabinger I, Pasi K, et al.
Res Pract Thromb Haemost
. 2022 Aug;
6(5):e12760.
PMID: 35910942
Background: Surgical procedures impose hemostatic risk to people with hemophilia, which may be minimized by optimal factor (F) replacement therapy. Methods: This analysis evaluates the efficacy and safety of extended...
3.
Parnes A, Mahlangu J, Pipe S, Paz-Priel I, Lehle M, Trask P, et al.
Haemophilia
. 2021 Oct;
27(6):e772-e775.
PMID: 34623725
No abstract available.
4.
van Galen K, dOiron R, James P, Abdul-Kadir R, Kouides P, Kulkarni R, et al.
J Thromb Haemost
. 2021 Jul;
19(8):1883-1887.
PMID: 34327828
Hemophilia A and B predominantly attracts clinical attention in males due to X-linked inheritance, introducing a bias toward female carriers to be asymptomatic. This common misconception is contradicted by an...
5.
Mahlangu J
Front Med (Lausanne)
. 2021 May;
8:670526.
PMID: 34026796
The unprecedented progress in addressing unmet needs in haemophilia care to date includes developing several novel therapies that rebalance haemostasis by restoring thrombin generation in patients with haemophilia A or...
6.
Oldenburg J, Tran H, Peyvandi F, Nunez R, Trask P, Chebon S, et al.
Haemophilia
. 2021 Feb;
27(3):398-407.
PMID: 33576546
Introduction: Real-world data on health-related outcomes in persons with haemophilia A (PwHA) can provide useful information for improving patient care. The global, non-interventional study (NIS; NCT02476942) prospectively collected high-quality data...
7.
Kempton C, Trask P, Parnes A, Niggli M, Campinha-Bacote A, Callaghan M, et al.
Haemophilia
. 2021 Jan;
27(2):221-228.
PMID: 33506955
Introduction: Emicizumab is a subcutaneously (SC) administered prophylactic agent for persons with haemophilia A (PwHA). As part of its clinical development, a new instrument was required to measure treatment satisfaction....
8.
Mancuso M, Mahlangu J, Pipe S
Lancet
. 2021 Jan;
397(10274):630-640.
PMID: 33460559
Congenital haemophilia A (factor VIII deficiency) and B (factor IX deficiency) are X-linked bleeding disorders. Replacement therapy has been the cornerstone of the management of haemophilia, aiming to reduce the...
9.
Pipe S, Kruse-Jarres R, Mahlangu J, Pierce G, Peyvandi F, Kuebler P, et al.
J Thromb Haemost
. 2020 Dec;
19 Suppl 1:21-31.
PMID: 33331042
Background: Despite recent therapeutic advances, life expectancy in persons with congenital hemophilia A (PwcHA) remains below that of the non-HA population. As new therapies are introduced, a uniform approach to...
10.
Peyvandi F, Mahlangu J, Pipe S, Hay C, Pierce G, Kuebler P, et al.
J Thromb Haemost
. 2020 Dec;
19 Suppl 1:32-41.
PMID: 33331041
Background: As the first non-factor replacement therapy for persons with congenital hemophilia A (PwcHA), emicizumab's safety profile is of particular interest to the community. Objectives: We applied an algorithm for...